Seattle Genetics Moves Antibody-Drug Conjugate Into Phase III For Hodgkin’s Lymphoma
This article was originally published in The Pink Sheet Daily
Executive Summary
SGN-35 trial kicks off in first quarter under a special protocol assessment, with an NDA filing targeted for 2011.
You may also be interested in...
Takeda Partners With Seattle Genetics On Lymphoma Candidate In Pivotal Trials
Just days after Seattle Genetics lost Roche/Genentech as a partner for dacetuzumab (SGN-40), a CD40 antibody in development for lymphomas and multiple myeloma, the company has a new Big Pharma partner to head into the new year with. Seattle Genetics and Takeda's Millennium oncology unit announced a licensing deal Dec. 15 for brentuximab vedotin (SGN-35), an antibody-drug conjugate in development for lymphomas
Takeda Partners With Seattle Genetics On Lymphoma Candidate In Pivotal Trials
Days after losing Roche/Genentech as a partner for dacetuzumab, Seattle Genetics signs Takeda as a partner for a late-stage antibody-drug conjugate.
Takeda Partners With Seattle Genetics On Lymphoma Candidate In Pivotal Trials
Days after losing Roche/Genentech as a partner for dacetuzumab, Seattle Genetics signs Takeda as a partner for a late-stage antibody-drug conjugate.